

Summary and Future Steps: EFPIA perspectives by Donald R. Stanski, MD

- .What has been unique about this meeting?
- .What have been the major themes from the BOS sessions?
 - . BOS1:Significant opportunity in systems/pharmacology approaches
 - . BOS2:Get the Dose Right is fundamental M&S
 - . BOS3:Special populations-much opportunity, need to focus
 - . BOS4:Multiple important issues due to direct regulator interactions
- .Why is the regulatory role so important to drive the future?
- .What learning is there from the FDA Pharmacometric efforts?
- .What might the path forward look like?